Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in ...

SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Q32 Bio Inc. (QTTB) on Tuesday reported a loss of $14.2 million in its fourth quarter. The Waltham, Massachusetts-based company said it had a loss ...

In a report released on April 16, Thomas Smith from Leerink Partners maintained a Hold rating on Q32 Bio (QTTB – Research Report). The company’s shares closed yesterday at $2.12. Discover ...

(RTTNews) - Q32 Bio Inc. (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) at the 2025 American Academy ...

Earnings Estimate Revisions for Q32 Bio This gene editing company is expected to earn -$4.14 per share for the fiscal year ending December 2025, which represents a year-over-year change of 37.1%.